Browse by Audience
Skip to content
Papers of the Week
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Abstract
Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and safety of OCA in patients with PSC.